SYD985 is a HER2-targeting antibody–drug conjugate (ADC) based on trastuzumab and vc-seco-DUBA, a cleavable linker-duocarmycin payload. To evaluate the therapeutic potential of this new ADC, mechanistic in vitro studies and in vivo patient-derived xenograft (PDX) studies were conducted to compare SYD985 head-to-head with T-DM1 (Kadcyla), another trastuzumab-based ADC. SYD985 and T-DM1 had similar binding affinities to HER2 and showed similar internalization. In vitro cytotoxicity assays showed similar potencies and efficacies in HER2 3+ cell lines, but in cell lines with low HER2 expression, SYD985 was 3- to 50-fold more potent than T-DM1. In contrast with T-DM1, SYD985 efficiently induced bystander killing in vitro in HER2-negative (HER2 0) cells mixed with HER2 3+, 2+, or 1+ cell lines. At pH conditions relevant for tumors, cathepsin-B cleavage studies showed efficient release of the active toxin by SYD985 but not by T-DM1. These in vitro data suggest that SYD985 might be a more potent ADC in HER2-expressing tumors in vivo, especially in low HER2-expressing and/or in heterogeneous tumors. In line with this, in vivo antitumor studies in breast cancer PDX models showed that SYD985 is very active in HER2 3+, 2+, and 1+ models, whereas T-DM1 only showed significant antitumor activity in HER2 3+ breast cancer PDX models. These properties of SYD985 may enable expansion of the target population to patients who have low HER2-expressing breast cancer, a patient population with still unmet high medical need. Mol Cancer Ther; 14(3); 692–703. ©2015 AACR.
After many years of investigation, antibody–drug conjugates (ADC) finally find their way to clinical practice (1). The approval of the CD30-targeting ADC brentuximab–vedotin (marketed as Adcetris) for treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma (2–4) and the more recent approval of ado-trastuzumab emtansine (T-DM1, marketed as Kadcyla) for the treatment of HER2-positive metastatic breast cancer (5–8), confirm the potential of ADCs in cancer treatment. The promise of ADCs as a new class of drugs in oncology is further illustrated by the fact that currently over 30 ADCs are in clinical development and many more are in preclinical programs (1).
The approval of T-DM1 was based on studies demonstrating increased progression-free survival and overall survival time of patients with metastatic HER2-positive breast cancer (5–8) at a dosing regimen (3.6 mg/kg/3 weeks) that was well tolerated. The introduction of T-DM1 has added great value to the therapeutic armamentarium for patients with HER2-positive metastatic breast cancer; nevertheless, the patient population that might benefit from a HER2-targeting ADC could be expanded by a more effective HER2-targeting ADC. T-DM1 is approved for the treatment of HER2-positive metastatic breast cancers, defined as IHC-HER2 3+ or FISH-positive/IHC-HER2 2+. According to these criteria, approximately 20% to 25% of all metastatic breast cancer patients are currently eligible for T-DM1 therapy (9, 10). A HER2-targeting drug that has a clinical benefit in patients whose tumor is FISH-negative but has detectable IHC HER2 expression (2+ and 1+) would at least double that population (10, 11).
We recently described SYD985, a new HER2-targeting ADC based on the cleavable linker-duocarmycin payload, valine-citrulline-seco DUocarmycin hydroxyBenzamide Azaindole (vc-seco-DUBA), conjugated to trastuzumab (12). SYD985, and its unfractionated precursor SYD983, showed high antitumor activity in HER2-positive breast cancer patient-derived xenograft (PDX) models in mice (12). To further assess the potential of SYD985, a series of mechanistic in vitro studies and breast cancer PDX studies were initiated to directly compare the antitumor activity of SYD985 with T-DM1 in models with different HER2 status. The preclinical profile described in the present paper supports clinical studies with SYD985, particularly studies that aim at extending the target population to patients with metastatic breast cancer tissue that has FISH-negative/IHC-HER2 2+ and 1+ status.
Materials and Methods
SYD985 and T-DM1
SYD985 was prepared as described previously (12–15). Two batches of T-DM1 from Roche were obtained, EU batch N0001B02 and US batch 535405. Both batches of T-DM1 showed similar in vitro potency and efficacy data on a panel of four human tumor cell lines (Supplementary Fig. S1). Head-to-head studies comparing T-DM1 with SYD985 in this paper were conducted with batch N0001B02.
Cancer cell lines and quantification of HER2 levels
Within the period 2011–2014, human tumor cell lines SK-BR-3, UACC-893, NCI-N87, SK-OV-3, MDA-MB-175-VII, ZR-75-1, NCI-H520, and SW-620 were obtained from ATCC. No further cell-line authentication was conducted. NCI-N87, ZR-75-1, MDA-MB-175-VII, SW-620, and NCI-H520 cells were cultured in RPMI-1640 media (Lonza) supplemented with 10% v/w FBS, which was heat inactivated (HI; Gibco- Life Technologies), at 37°C in a humidified incubator containing 5% CO2. SK-BR-3 and SK-OV-3 cells were maintained in McCoys 5A medium (Lonza) containing 10% v/w FBS HI, and UACC-893 cells were cultured in DMEM/F-12, Glutamax supplement (Gibco-Life Technologies) containing 20% v/w FBS (Gibco-Life Technologies).
HER2/neu antigen expression on the surface of human tumor cell lines was quantified using the DAKO Qifikit (DAKO), according to the manufacturer's protocol.
Cell viability assays
Cells in complete growth medium were plated in 96-well plates (90 μL/well) and incubated at 37°C, 5% CO2 at the following cell densities: 6500 SK-BR-3, 10000 UACC-893, 10000 NCI-N87, 2000 SK-OV-3, 2500 MDA-MB-175-VII, 2500 ZR-75-1, 4000 SW-620, and 5000 NCI-H520 cells per well. After an overnight incubation, 10 μL of mAb, drug, and/or active toxin (seco-DUBA) was added. Serial dilutions were made in culture medium. For the studies with a shorter exposure of the ADCs, cells were washed once with complete growth medium after 6 and 24 hours, followed by addition of 100 μL of the same medium. Cell viability was assessed after 6 days, unless indicated otherwise, using the CellTiter-Glo (CTG) luminescent assay kit from Promega Corporation according to the manufacturer's instructions and as detailed previously (12). Percentage survival was calculated by dividing the measured luminescence for each drug or ADC concentration with the average mean of untreated cells (only growth medium) multiplied by 100.
Fluorescent labeling of SYD985 and T-DM1
SYD985 and T-DM1 were labeled with an Alexa Fluor 488 reactive dye from Invitrogen, which has a tetrafluorophenyl ester moiety that reacts efficiently with primary amines of proteins to form stable dye–protein conjugates. Before labeling, T-DM1 or SYD985 was desalted into PBS and the protein concentration was determined using UV absorbance at 280 nm. The pH was adjusted to pH 8.3 and labeling was performed by incubation of T-DM1 or SYD985 solution with an Alexa Fluor 488 solution in DMA in a 9:1 molar ratio (dye:mAb) for 1 hour. After incubation, labeled T-DM1 or SYD985 was buffer exchanged into PBS using gel filtration. The degree of labeling was calculated from the UV absorbance at 280 and 495 nm according to the documentation supplied with the labeling kit and was found to be 1.4 for SYD985 and 1.8 for T-DM1.
Internalization was performed as detailed previously (11). Cells (2,000,000 cells/tube) were incubated for 1 hour at 4°C with 2 mL of 3 μg/mL Alexa Fluor 488 (AF488)-labeled SYD985 or 2 mL of 3 μg/mL Alexa Fluor 488-labeled T-DM1. These cells were split into two groups after a wash step with ice-cold 1× PBS (Lonza) containing 0.2% v/w BSA (Sigma-Aldrich). For one part of the cells, internalization was assessed upon incubation at 37°C (100 μL cell solution/vial). The other part was used as control cells for the total cell surface binding and was incubated at 4°C. After the indicated incubation times, cells were washed three times with ice-cold 1× PBS-0.2% v/w BSA buffer. The remaining surface expression was visualized after quenching with 50 μL of anti-Alexa Fluor 488 Rabbit IgG Ab (1:30 dilution; Molecular Probes, Life Technologies) for 30 minutes at 4°C. Fluorescence intensities were determined by flow cytometry (BD FACSVerse) and indicated as the median fluorescence intensity (MFI). Internalization was quantified by calculating the percentage of internalization with the following formula: MFI of the internalized signal (surface AF488-labeled ADC quenched by anti-AF488 and corrected for untreated cells) divided by the total bound AF488-labeled ADC (unquenched cells corrected for untreated cells) multiplied with 100.
Enzymatic cleavage by cathepsin B
0.1 mg/mL of the ADC or 10 μmol/L active toxin (seco-DUBA) was mixed with 5 μg/mL human liver cathepsin B (Calbiochem) in 0.1 mol/L Na-acetate buffer, pH 5, 6, 6.5 or 7, supplemented with 4 mmol/L DTT. As a control, ADCs or seco-DUBA was diluted in culture medium to a 0.1 mg/mL concentration. After 4 hours of preincubation at 37°C, serial dilutions were made from each stock solution in culture medium and 10 μL was added to each well of a 96-wells plate. SW-620 cells (90 μL; 4,000 cells/well) were cultured with these ADCs or seco-DUBA for 6 days, and the cell viability was measured after 6 days using the CTG assay kit.
Bystander killing assay
HER2-positive SK-BR-3, SK-OV-3, or MDA-MB-175-VII cells were mixed with HER2-negative NCI-H520 cells in McCoy's 5A medium containing 10% v/w FBS HI. Five thousand cells per well of each cell type (1:1 ratio), or indicated otherwise, were added to a 96-well plates (90 μL/well). Single cultures were seeded at a density of 5,000 cells/well (90 μL/well). After 4 hours, 10 μL of each ADC or seco-DUBA was added. Serial dilutions were made in culture medium. Cell viability was assessed after 6 days, unless indicated otherwise, using the CTG luminescent assay kit.
Bystander FACS analyses
NCI-H520 cells were labeled with CellTrace Violet (Life Technologies) according to the manufacturer's instructions. Similar as to the bystander killing studies, a 1:1 ratio of HER2-positive and HER2-negative cells were mixed (10,000 cells/well of each cell type) and plated in 96-well plates (90 μL/well). Single cultures were seeded at a density of 10,000 cells/well (90 μL/well). After an overnight incubation, 10 μL of 1 μg/mL ADC or (seco-pro) drug was added. Cells were detached with 0.1%-trypsin-EDTA after the indicated incubation time and washed with FACS buffer (ice-cold 1× PBS containing 0.2% v/w BSA). Pellet was resuspended in 150 μL FACS buffer supplemented with 0.7 μmol/L TO-PRO-3 Iodide (Life Technologies). Fluorescence intensities were determined for 1 minute using the high-sensitivity mode on the BD FACSVerse. The CellTrace violet labeled NCI-H520 cells allowed detection and gating between the HER2-negative labeled NCH-H520 cells and the HER2-positive nonlabeled cells. Dead cells were gated using TO-PRO-3 Iodide. The percentage of gated viable cells was calculated on the basis of the total cell population (viable plus dead cells is 100%).
Cleavage by CES1c
A 100 μg/mL concentration of SYD985 was spiked in human K2-EDTA plasma together with 0, 10, 100, 200, and 400 μg/mL recombinant mouse carboxylesterase 1c (CES1c, Cusabio Biotech). After 96 hours of incubation at 37°C, plasma samples were snap frozen in liquid nitrogen and stored at −80°C until bioanalysis. SYD985 ADC (conjugated antibody) levels and total antibody (TAb) levels in plasma were quantified using an ELISA-based method as described previously (12).
Cell line and patient-derived xenograft studies
The in vivo antitumor activity of SYD985 versus T-DM1 was tested as single-dose therapy in the BT-474 cell line-derived xenograft model, and a selection of breast cancer PDX. The BT-474 model was performed at Oncodesign. PDX models used were MAXF 1162, MAXF MX1, and MAXF 449 (Oncotest), ST313 (South Texas Accelerated Research Therapeutics), HBCx-34 and HBCx-10 (Xentech). Initial tumor volumes at the day of randomization and treatment ranged from 52 to 379 mm3. All studies were approved by the local animal care and use committees according to established guidelines. The HER2 FISH and IHC status of the BT-474 tumor and tumors from the PDX models as determined by the CROs were independently confirmed as described below in this Materials and Methods section. The characteristics of all tumors used in this paper are summarized in Supplementary Table S1. Representative photographs of the HER2 IHC staining are presented in Supplementary Fig. S2. Studies were conducted as detailed previously (12).
HER2 gene amplification
HER2/neu gene amplification was determined by in situ hybridization (ISH) in formalin-fixed, paraffin-embedded human breast cancer tissue specimens with a Ventana-Roche automated platform and an inform HER2 Dual ISH DNA probe cocktail, UltraView SISH DNP Detection kit, and UltraView Red ISH Dig detection kit, as detailed by the supplier.
HER2 IHC staining
Tissue sections of formalin-fixed paraffin-embedded tumor xenograft samples were prepared. IHC was performed on the Discovery automated platform (Ventana-Roche) with the primary Ab anti-HER2/neu (4B5) rabbit monoclonal (Ventana-Roche, ref 790-4493) and the detection kit OmniMap RB HRP (anti-rabbit multimer, Ventana-Roche reference 760-4311) associated to the chromogenic kit ChromoMap DAB (Ventana-Roche reference 760-159, as detailed by the supplier.
PK studies and bioanalytical assays
BT-474 tumor-bearing female balb/c nu/nu mice and female cynomolgus monkeys were dosed intravenously with 1, 3, and/or 5 mg/kg SYD985 or T-DM1. Blood samples were taken at multiple time point hours after dosing, cooled on ice water, and processed to plasma as soon as possible. Plasma samples were snap frozen in liquid nitrogen and stored at −80°C until bioanalysis. SYD985 ADC (conjugated antibody) levels and TAb levels in plasma were quantified using an ELISA-based method as described previously (12). The conjugated antibody assay uses an anti-toxin antibody as solid phase and a biotinylated anti-idiotype mini antibody for detection. In the TAb assay, the anti-idiotype mini-antibody is used as solid phase instead of the anti-toxin antibody. A validated LC/MS-MS based method was used for quantification of active toxin (DUBA) in plasma. A competitive EIA-based method (KTR 756 DM1 ADC EIA kit, Epitope Diagnostics) was used for the determination of T-DM1 levels in plasma according to the protocol of the supplier.
Statistical analyses of in vitro cytotoxicity assays and in vivo xenograft experiments were performed as detailed previously (12).
SYD985 (Fig. 1) was synthesized and prepared as described previously (12). In short, vc-seco-DUBA was coupled to cysteine residues of trastuzumab after partial reduction of the interchain disulfides. SYD985 was further purified by hydrophobic interaction chromatography to deliver a well-defined ADC consisting of predominantly species with a drug to antibody ratio (DAR) of 2 and 4, yielding a mean DAR of 2.8. Some crucial features of the antibody, such as binding affinity and induction of ADCC activity in vitro were not affected by conjugation (data not shown) as was also published for SYD983, the unfractionated form of SYD985 (12).
Binding and internalization of SYD985 and T-DM1
Binding capacity and percentage of internalization of SYD985 and T-DM1 were determined in time using flow-cytometric analyses in cell lines SK-BR-3 (breast carcinoma), SK-OV-3 (ovarian carcinoma), and MDA-MB-175-VII (breast carcinoma), which are classified as HER2 3+, 2+, and 1+, respectively. SYD985 and T-DM1 showed a similar binding activity (EC50 0.4–0.9 μg/mL) to cell surface HER2, irrespective of the HER2 expression level. The rank order of maximum binding capacity of both SYD985 and T-DM1 correlated with the number of HER2-binding sites on the tumor cells. Receptor-mediated endocytosis of Alexa Fluor 488 (AF488)-labeled SYD985 into HER2-positive tumor cells was compared with the uptake of AF488-labeled T-DM1. Fluorescence of each internalized ADC was measured by flow cytometry after quenching of the surface-bound AF488-labeled ADC with an anti-AF488 antibody. A limitation of this approach is the incomplete quenching of the cell-surface bound AF488-labeled ADCs, as is evident from the 4°C controls. This is in line with the supplier instructions that described a maximum quenching of the AF488 dye up to 90% or lower in the case of conjugated AF488 dye. The kinetics of uptake for SYD985 and T-DM1 were comparable. Also the maximum percentages of internalization for both ADCs are within the same order of magnitude (Fig. 2A).
Cytotoxicity of SYD985 versus T-DM1 in vitro
A set of eight cell lines was selected on the basis of their published HER2 status; breast carcinomas SK-BR-3 and trastuzumab-resistant UACC-893 (both HER2 3+), gastric carcinoma NCI-N87 (HER2 3+), ovarian carcinoma SK-OV-3 (HER2 2+), breast carcinomas MDA-MB-175-VII and ZR-75-1 (both HER2 1+), and metastatic colon carcinoma SW-620 and lung adenocarcinoma NCI-H520 (both HER2 0). The HER2 status of these cell lines was confirmed by Qifi-kit analysis (Supplementary Fig. S3). We have previously (12) shown that SK-BR-3, SK-OV-3, SW-620, and NCI-H520 all are highly sensitive to the active toxin seco-DUBA, decreasing the cell viability with potencies between 0.08 nmol/L and 0.4 nmol/L after a 6-day treatment. Cytotoxicity studies in NCI-N87 and UACC-893 cell lines, confirmed high sensitivity to seco-DUBA with potencies of 0.2 nmol/L (Supplementary Fig. S4A). Because seco-DUBA was less potent against MDA-MB-175-VII (2.5 nmol/L) and ZR-75-1 (8.2 nmol/L) cells at 6 days, we extended the treatment time up to 12 days with corresponding IC50 values of 0.1 and 0.2 nmol/L, respectively (Supplementary Fig. S4A). As shown in Fig. 2B, SYD985 and T-DM1 demonstrate similar potencies in the HER2 3+ cell lines SK-BR-3, UACC-893, and NCI-N87. IC50 values are 6.9 and 15.7 ng/mL in SK-BR-3, 54.1 and 35.9 ng/mL in UACC-893, and 24.5 and 44.9 ng/mL in NCI-N87, for SYD985 and T-DM1, respectively. Although SYD985 and T-DM1 both potently kill UACC-893 cells, we confirmed lack of responsiveness to trastuzumab (Supplementary Fig. S4B; refs. 16, 17). Importantly, SYD985 retained its activity in cell lines with lower HER2 expression, whereas T-DM1 became less potent with IC50 values of 32.4 and 112.1 ng/mL in SK-OV-3, 67.4 and 313.9 ng/mL in MDA-MB-175-VII, and 14.9 and >1,000 ng/mL in ZR-75-1, for SYD985 and T-DM1, respectively (see Supplementary Table S2 for the percentage efficacy and 95% confidence intervals). Neither SYD985 nor T-DM1 was able to kill HER2-negative SW-620 or NCI-H520 cells (Fig. 2B), indicating that both ADCs mediate their cytotoxic effect through HER2. Thus, overall these data show that in cell lines with lower HER2 expression (HER2 2+/1+), SYD985 is significantly (factor 3–50) more potent than T-DM1.
Next, we studied the relation between exposure times to ADC and cell killing after 6 days, in three cell lines with different HER2 expression levels. SK-BR-3, SK-OV-3, and MDA-MB-175-VII cells were exposed to SYD985 and T-DM1 for 6 and 24 hours, washed to remove ADCs, and cultured until 6 days, except for MDA-MB-175-VII cells (12 days). As control, cells were treated with ADCs during the entire incubation of 6 and 12 days. A short incubation of 6 hours was enough for both SYD985 and T-DM1 to potently kill SK-BR-3 cells after 6 days, indicating that sufficient amounts of the respective toxins were loaded inside cells to induce killing (Fig. 2C). For SK-OV-3 and MDA-MB-175-VII cells, in line with their lower HER2 expression, a 6- or even 24-hour exposure to ADC did not induce maximum killing, suggesting that recycling of HER2 after internalization and reloading of cells with ADC is needed for potent killing of cells with low HER2 levels (Fig. 2C).
Protease sensitivity and bystander killing in vitro
Proteases, like cathepsin B, are highly expressed in a wide variety of tumors, including breast cancer tumors, and can also be active extracellularly through secretion by malignant cells (18, 19). The sensitivity of SYD985 and T-DM1 to cathepsin B cleavage was evaluated at pH 5 to mimic the acidic milieu in lysosomes and at pH 6, 6.5, and 7 to mimic pH in endosomes and tumor environment. SYD985 and T-DM1 were exposed for 4 hours to activated cathepsin B and release of active toxin was quantified by measuring cytotoxic activity on HER2-negative SW-620 cells. In the absence of cathepsin B, SYD985 did not reduce cell viability of SW-620 cells. However, 4 hours preincubation of SYD985 with cathepsin B, in a pH range between 5 to 7, resulted in potent killing of SW-620 cells, indicating release of active toxin (Fig. 3A). Preincubation of T-DM1 with cathepsin B did not result in cytotoxic activity (Fig. 3A), which is in line with the nature of its noncleavable thioether linker. These data show that SYD985, most likely through its valine-citrulline motif, and in contrast with T-DM1, rapidly releases active toxin through cathepsin B cleavage, an enzyme abundantly present in the tumor cell and microenvironment. In mice, an enzyme present in plasma can cleave vc-seco-DUBA and cause release of active toxin. Adding 1% mouse plasma causes a dramatic shift in cytotoxic activity of SYD985 on HER2-negative SW620 cells, in contrast with human plasma (Fig. 3A). In vitro incubation of SYD985 with recombinant mouse carboxylesterase 1C does release this active species as well (Supplementary Fig. S4B), suggesting that in mouse plasma, carboxylesterase 1C might be responsible for cleavage of vc-seco-DUBA. The position at which this cleavage occurs is most likely the carbamate group connecting the alkylating moiety of the duocarmycin to the linker (Fig. 1) since previous studies with valine-citrulline linkers have indicated that this site is quite stable in mouse plasma (20).
Next, the ability of SYD985 and T-DM1 to kill HER2-negative bystander tumor cells was explored. NCI-H520 (HER2 0) cells were cocultured (5,000 cells of each cell type per well) with one of the following HER2-positive cell lines, SK-BR-3 (HER2 3+), SK-OV-3 (HER2 2+), or MDA-MB-175-VII (HER2 1+). Cells were treated for 6 days with either SYD985, its nonbinding isotype control ADC, T-DM1, or the active toxin seco-DUBA. NCI-H520 cells were insensitive (IC50 > 50 nmol/L) to SYD985, its isotype control ADC, and T-DM1 but were sensitive for seco-DUBA (IC50 0.04 nmol/L; Fig. 3B and Supplementary Fig. S4D). As shown in Fig. 3B, treatment of SK-BR-3/NCI-H520 and SK-OV-3/NCI-H520 cocultures with 1 μg/mL SYD985 resulted in killing of the HER2 0 NCI-H520 cells, whereas the nonbinding isotype control ADC and T-DM1 did not. Coculturing of cells for 6 days resulted in a dissimilar distribution of the percentage of viable HER2-positive and HER2-negative cells, which was indicated by the results of the isotype control ADC and is most likely due to differences in growth rates.
Despite these differences in growth rates, FACS confirmed (Fig. 3C) that in the presence of SYD985, HER2 0 cells were killed when cocultured with SK-BR-3 and SK-OV-3 cells, and not in the presence of T-DM1. Bystander killing in the MDA-MB-175-VII/NCI-H520 coculture was not so evident after 6 days of incubation, but became clearly visible after 12 days of incubation (Supplementary Fig. S5A). To strengthen these bystander killing studies, we determined the minimum proportion of HER2 3+ target cells required for SYD985-mediated bystander killing of HER2 0 cells. Different ratios of HER2-positive SK-BR-3 and HER2-negative NCI-H520 cells were cocultured, resulting in 100%, 80%, 60%, 40%, 20%, and 0% HER2-positive cells (Supplementary Fig. S5B). With only 20% of HER2 3+ target cells, SYD985 was still able to kill 65% of the mixed cell population indicating bystander killing. In contrast, under the same condition, in which 20% of the HER2 3+ target cells are present, T-DM1 was able to kill 9% of the cocultured cells (Supplementary Fig. S5B).
These findings indicate that active toxins are released after processing of SYD985 by HER2-positive cells that are either HER2 3+, 2+, or 1+, resulting in the killing of HER2 0 cells in the immediate vicinity. These results are consistent with previously reported results showing that at least some cleavable linkers could facilitate bystander killing, whereas a noncleavable ADC was not able to kill antigen-negative bystander cells (21, 22).
Taken together, this in vitro profile indicates that SYD985 might show more antitumor potential than T-DM1, especially in tumors that express low levels of HER2 and/or are heterogeneous in their HER2 expression.
In vivo antitumor activity of SYD985 versus T-DM1
In vivo antitumor activity of SYD985 versus T-DM1 was tested in a cell line (BT-474) xenograft and a range of breast cancer PDX models, with different HER2 status. After single-dose administration, tumor growth was inhibited in a dose-dependent manner in the BT-474 cell line xenograft model and the MAXF1162 breast cancer PDX model (both HER2 3+; Fig. 4A and B). SYD985 is significantly more active (7 out of 8 mice showed complete tumor remission with SYD985 at 5 mg/kg vs. none for T-DM1) than T-DM1 in these models. In contrast with 1 mg/kg T-DM1, 1 mg/kg SYD985 significantly reduced tumor volume compared with the vehicle group in the BT-474 xenograft, and based on the AUCs (tumor volume vs. time) of the tumor size data, 5 mg/kg SYD985 is significantly more active (P = 0.0148) than 5 mg/kg T-DM1. In MAXF 1162, also a HER2 3+ tumor, there was no statistically significant difference between AUCs of the 10 mg/kg groups at the end of the study (day 72). In FISH negative/IHC HER2 2+ breast cancer PDX models, SYD985 was consistently more active than T-DM1 (Fig. 4C and D). The difference was most apparent in the HBCx-34 model (Fig. 4D) showing a complete response in 1 out of 8 mice at 3 mg/kg SYD985 and in 4 out of 8 mice when treated with 10 mg/kg. T-DM1 was not active. In the FISH-negative/IHC 1+ MAXF 449 model (Fig. 4E), SYD985 was dosed in a lower range: 0.3, 1, and 3 mg/kg, and it was observed that 1 and 3 mg/kg SYD985 showed similar efficacy compared with 30 mg/kg T-DM1. Remarkably, in two other FISH-negative/IHC HER2 1+ triple-negative breast cancer PDX models MAXF-MX1 and HBCx-10, SYD985 appeared to be particularly active (Fig. 4F and G). In MAXF-MX1 (Fig. 4F), 4 out of 6 mice in the 1 mg/kg group showed a complete response to SYD985, at 3 mg/kg all, mice had complete tumor remission. In the HBCx-10 (Fig. 4G), 4 out of 7 mice showed a complete response at 1 mg/kg as did all mice in the 3 mg/kg group. In contrast, T-DM1, even when dosed up to 30 mg/kg, showed no significant antitumor activity in these models.
The nonbinding isotype control ADC, which is vc-seco-DUBA conjugated to rituximab (prepared with a similar protocol as SYD985 and with similar DAR and HIC profile), showed, at similar dosages, significantly less antitumor activity than SYD985 in the HER2 3+ xenograft models (Fig. 5A and B), indicating that the effect of SYD985 is largely HER2 mediated. Like for the BT-474 and MAXF1162, also for both the HER2 2+ PDX models, antitumor activity of the nonbinding ADC was observed, illustrative of a bystander effect. However, at the lower dosages, HER2-mediated effects clearly contributed to the antitumor activity of SYD985 (Fig. 5C and D). At higher dose (10 mg/kg), this difference between isotype control ADC and SYD985 was no longer apparent in tumor model ST313 (Fig. 5C). Finally, also for the three FISH-negative/IHC 1+ models, SYD985-mediated antitumor effects could be attributed to be largely due to HER2-mediated effects. Effects induced by the isotype control ADC indicated for nontarget mediated antitumor activity as well (Fig. 5E–G).
In all PDX studies, in all experimental groups, body weight was determined twice a week as a measure for toxicity and potential overdosing. None of the animals in any of the experimental groups in any of the PDX studies showed significant change in body weight.
Taken together, these data show that, in contrast with T-DM1, SYD985 is active in breast cancer PDX models with low (2+ and 1+) HER2 status.
In vivo plasma kinetics of SYD985 and T-DM1 were studied in BT-474 tumor-bearing mice, since, in contrast with results reported for T-DM1 (23, 24), we observe a difference in PK between tumor-bearing mice and healthy balb/c mice (12). This is probably caused by target mediated drug disposition, dependent on HER-2 expression levels in the tumor model used, and dependent on the degree of saturation of HER-2 target molecules at the given dose.
As shown in Fig. 6A and Supplementary Table S3, SYD985 shows high clearance of conjugated antibody (18.2–19.7 mL/hour/kg). This is in line with sensitivity of vc-seco-DUBA–based ADCs to esterase activity in mouse plasma. This sensitivity for esterases is mouse CES1c specific, because SYD985 shows high in vitro stability in plasma from CES1c knockout mice, human, and monkey plasma (12). Furthermore, these findings were confirmed in vivo, showing low clearance of conjugated antibody in CES1c knockout mice (0.51 mL/hour/kg; Supplementary Fig. S6) and monkey (0.52 mL/hour/kg). Remarkably, in monkey, conjugated antibody levels were hardly different from TAb concentrations (clearance of 0.38 mL/hour/kg) and T-DM1 concentrations (clearance of 0.64 mL/hour/kg; ref. 25), while active toxin (DUBA) plasma levels remain extremely low (Fig. 6B). Mean Cmax DUBA level was 0.018 ng/mL versus 5.85 ng/mL for DM1 (25), both dosed at 3 mg/kg ADC in female monkeys.
After T-DM1 administration to mice, ADC clearance is much lower (1.8–1.7 mL/hour/kg) compared with SYD985 (Fig. 6A and Supplementary Table S3). This is in line with published PK data for T-DM1 (24) showing a clearance of 0.75 to 0.9 mL/hour/kg for T-DM1, especially when taking into account that the tumor model used shows higher clearance compared with nontumor-bearing mice. Unfortunately, a true quantitative comparison of ADC exposure after dosing of T-DM1 or SYD985 is not possible due to differences between and limitations of the bioanalytical tools. Nevertheless, it is clear that SYD985 shows much higher ADC clearance, most likely due to esterase mediated cleavage of the linker drug, although it cannot be ruled out that other causes of deconjugation, like maleimide exchange to albumin, may contribute. As a consequence, a higher formation of naked antibody is seen for SYD985 compared with T-DM1 in mice.
Mechanism of antitumor activity in vivo
To evaluate whether the early release of seco-DUBA in mouse plasma after dosing of SYD985 might affect or contributes to antitumor activity, we performed a predosing study in the MAXF-MX1 and HBCx-34 PDX models. In both models, a pretreatment of 24 hours with a high dose of trastuzumab blocked antitumor activity of an active dose of SYD985 (Fig. 6C and D). These data confirm for these two models the earlier conclusion that HER2-mediated targeting to the tumor is essential for antitumor activity. It furthermore proves that antitumor activity of SYD985 at least in these two models is not driven by the early release of active toxin in mouse plasma as a result of mouse carboxylesterase cleavage.
To assess the therapeutic value of SYD985 for treatment of patients with breast cancer, we compared its preclinical antitumor activity head-to-head to that of T-DM1 in a series of high and low HER2-expressing breast cancer PDX models. In addition, we have performed mechanistic studies in vitro comparing SYD985 to T-DM1 for cytotoxic potency, protease sensitivity, and bystander induction.
SYD985 and T-DM1 share trastuzumab as the targeting mAb, and indeed binding affinities and internalization of the ADCs on several cell lines in vitro were similar. Thus, differences between both ADCs should most likely be attributed to either the linker and/or the toxin. Small differences were evident for the respective in vitro cytotoxicity in high-expressing HER2 (3+) cell lines, and antitumor activity studies in vivo in high HER2-expressing breast cancer xenografts. For both ADCs, these data are in line with previous publications (12, 26–28), although this first head-to-head comparison presented here shows that SYD985, especially in vivo, is more active than T-DM1 in high HER2-expressing tumors.
More striking differences were observed in studies in low HER2-expressing cell lines and tumors. SYD985 is a 3- to 50-fold more cytotoxic than T-DM1 in low HER2-expressing (2+/1+) cell lines. Similar binding and internalization profiles of SYD985 and T-DM1 do not explain the difference in cytotoxicity potencies. Also, the payload per Ab cannot explain this difference because T-DM1 carries a mean of 3.7 maytansinoid molecules per ADC molecule versus a mean of 2.8 seco-DUBA moieties per molecule SYD985. Apparently, at least for the cell lines tested, cell-permeable duocarmycin seco-DUBA as released from SYD985 in endosomes and lysosomes is more efficient in cell killing than the maytansinoid payload which becomes available after complete lysosomal degradation of T-DM1 (29, 30). The nature of toxicity that both toxins induce is indeed different as the payload of T-DM1 is an antimitotic agent preventing microtubule assembly and thereby precluding mitosis in dividing cells (29, 30), whereas the toxic payload of SYD985 is a duocarmycin which alkylates DNA resulting in DNA damage, mitochondrial stress, impaired DNA transcription, and ultimately cell death in both dividing and nondividing cells. Potencies of the respective payloads might be different, but this is hard to assess as the free maytansine payload (carrying the lysine-conjugated linker) is cell impermeable and therefore will show an irrelevantly low in vitro cytotoxic activity.
Antitumor effects of SYD985 in vivo, also in the low HER2-expressing PDX models, were largely mediated through HER2, as demonstrated by two independent approaches, that is, the use of nonbinding isotype control ADCs and the blocking experiments where a trastuzumab pretreatment blocked SYD985-mediated antitumor activity. Differences in antitumor activities became qualitative when SYD985 and T-DM1 were studied for in vivo effects in low HER2-expressing breast cancer PDX models, where SYD985 shows potent antitumor activity and T-DM1 is inactive. In vitro data that might contribute to this striking difference in vivo includes sensitivity of the linker in SYD985 for cathepsin B cleavage and potent bystander killing observed for SYD985. T-DM1 contains a noncleavable linker which depends on complete digestion of the antibody moiety in lysosomes (31). The resulting DM1-containing lysine derivates induce cytotoxicity, however, they cannot or poorly diffuse across the plasma membrane outside the cell (22) which is in line with lack of bystander killing in our in vitro studies. In SYD985, a cleavable dipeptide valine-citrulline linker is used. Linker cleavage by cysteine proteases, such as cathepsin B, present in early- and late endosomes and lysosomes, results in subsequent release of membrane-permeable active toxin. This enables cell killing of HER2-positive cells but also cell death of neighboring nonantigen-expressing cells, in line with results of bystander studies in this paper.
Proteases, like cathepsin B, also reside in the interstitium of tumors. They are highly expressed in a wide variety of tumors, including breast cancer tumors, and secreted by malignant cells (18, 19, 32). Extracellular cleavage of vc-seco-DUBA may therefore induce a bystander effect where not only the HER2-targeted tumor cell is killed, but also neighboring cells. This additional mechanism for bystander killing is a possible explanation for the observed difference in antitumor activity of SYD985 compared with T-DM1 in low HER2-expressing and/or heterogeneous tumors. These data are in line with a previous publication where efficacy of ADCs with cleavable linkers were shown to be less dependent on target expression than ADCs with noncleavable linkers (33). This is also illustrated by the observed antitumor activity of the nonbinding isotype control of SYD985 that indicated that SYD985-mediated antitumor activity was not exclusively target mediated.
As was described previously (12), SYD985 shows a poor stability in mouse plasma and consequently poor kinetics in mice leading to a relatively low exposure. We have shown that the poor PK of SYD985 is due to the presence of a mouse-specific carboxylesterase, CES1c, which is not expressed in human or cynomolgus monkey (12, 34, 35). Currently the exact cleavage site is unconfirmed. Possibly, CES1c hydrolyzes the carbamate bond connecting the alkylating moiety of the duocarmycin to the linker (Fig. 1). CES1c activity and subsequent rapid cleavage of the linker drug in SYD985 lead to early release of active toxin in mouse plasma. In theory, active toxin in plasma in vicinity of the tumor might contribute to antitumor activity of SYD985, as mentioned previously (12). Experiments in the present paper showed that a high dose of trastuzumab blocks antitumor activity of an active dose of SYD985 in two PDX models. This demonstrates that (i) active toxin liberated in plasma or in close vicinity of the tumor does not contribute to antitumor activity and (ii) antitumor activity of SYD985 is largely HER2 mediated.
The exposure in terms of AUC does drive in vivo antitumor activity of SYD985 (12) as was also demonstrated for T-DM1 (23, 24). The strong antitumor activity of SYD985 in vivo in mice, is striking, especially if one compares the ADC (conjugated antibody) exposures for both ADCs which is, in mice, approximately 10-fold lower for SYD985 compared with T-DM1. Apart from that, CES1c-mediated release of the toxin in mice is accompanied by a substantial increase in naked mAb, which competes for the same HER2-binding sites and is inactive in these PDX models. Thus, efficacy studies with SYD985 in vivo in mice most likely lead to an underestimation of antitumor activity in species that will have higher exposure to SYD985, such as human. Monkey PK data and stability studies in human plasma indicate for excellent stability and predictable PK in man (12), thus SYD985 might show an even better efficacy profile in patients. Together, data presented here support the expectation that SYD985 has a clinically relevant efficacy in patients with breast cancer who have cancer tissue with low levels of HER2 expression.
Disclosure of Potential Conflicts of Interest
J.M. Lemmens has ownership interest (including patents) in Synthon. No potential conflicts of interest were disclosed by the other authors.
Conception and design: W.H.A. Dokter, M.M.C. van der Lee, P.G. Groothuis, R. Ubink, D.F. Egging, P.H. Beusker, P. Goedings, G.F.M. Verheijden, J.M. Lemmens
Development of methodology: M.M.C. van der Lee, R. Ubink, D.F. Egging, D. van den Dobbelsteen, P.H. Beusker
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): P.G. Groothuis, D. van den Dobbelsteen
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): W.H.A. Dokter, M.M.C. van der Lee, P.G. Groothuis, R. Ubink, M.A.J. van der Vleuten, T.A. van Achterberg, E.M. Loosveld, D.C.H. Jacobs, M. Rouwette, D.F. Egging, D. van den Dobbelsteen, P.H. Beusker, P. Goedings, G.F.M. Verheijden
Writing, review, and/or revision of the manuscript: W.H.A. Dokter, M.M.C. van der Lee, P.G. Groothuis, R. Ubink, D. Damming, D.F. Egging, D. van den Dobbelsteen, P.H. Beusker, P. Goedings, G.F.M. Verheijden, J.M. Lemmens, M. Timmers
Study supervision: W.H.A. Dokter, M. Timmers
This work was financially supported by Synthon Biopharmaceuticals BV.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The authors thank Prof. T. Hagemann (London, United Kingdom) for providing access to CES1c knockout mice.
Note: Supplementary data for this article are available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/).
- Received October 9, 2014.
- Revision received December 22, 2014.
- Accepted December 22, 2014.
- ©2015 American Association for Cancer Research.